Huperzine a attenuates mitochondrial dysfunction in β‐amyloid‐treated PC12 cells by reducing oxygen free radicals accumulation and improving mitochondrial energy metabolism
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
We observed previously that huperzine A (HupA), a selective acetylcholinesterase inhibitor, can counteract neuronal apoptosis and cell damage induced by several neurotoxic substances, and that this neuroprotective action somehow involves the mitochondria. We investigated the ability of HupA to reduce mitochondrial dysfunction in neuron‐like rat pheochromocytoma (PC12) cells exposed in culture to the amyloid β‐peptide fragment 25–35 (Aβ 25–35). After exposure to 1 μM Aβ 25–35 for various periods, cells exhibited a rapid decline of ATP levels and obvious disruption of mitochondrial membrane homeostasis and integrity as determined by characteristic morphologic alterations, reduced membrane potential, and decreased activity of ion transport proteins. In addition, Aβ 25–35 treatment also led to inhibition of key enzyme activities in the electron transport chain and the tricarboxylic acid cycle, as well as an increase of intracellular reactive oxygen species (ROS). Pre‐incubation with HupA for 2 hr not only attenuated these signs of cellular stress caused by Aβ, but also enhanced ATP concentration and decreased ROS accumulation in unharmed normal cells. Those results indicate that HupA protects mitochondria against Aβ‐induced damages, at least in part by inhibiting oxidative stress and improving energy metabolism, and that these protective effects reduce the apoptosis of neuronal cells exposed to this toxic peptide. © 2006 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pathways towards and Away from Alzheimer’s Disease
Mattson, M. P. (2004) · Nature · doi:10.1038/nature02621 · Cited by 3,052
Oxidative damage and mitochondrial decay in aging.
Shigenaga, M. K., Hagen, T. M., & Ames, B. N. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.23.10771 · Cited by 2,055 · cited 1×
“The mitochondrial respiratory chain, which consumes 85–90% of cellular oxygen, is the main source of oxygen free radicals (Shigenaga et al., 1994).”
BackgroundOxidative stress in neurodegeneration: Cause or consequence?
Andersen, J. K. (2004) · Nature Medicine · doi:10.1038/nrn1434 · Cited by 1,869 · cited 1×
“Normally, an organism or a cell uses an internal antioxidant defense system to maintain homeostasis in scavenging and production of free radicals (Andersen, 2004; Marlatt et al., 2004).”
BackgroundMetabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease
Minoshima, S., Giordani, B., Berent, S., Frey, K. A., Foster, N. L., & Kuhl, D. E. (1997) · Annals of Neurology · doi:10.1002/ana.410420114 · Cited by 1,802 · cited 2×
“Moreover, such cerebral metabolic abnormalities precede signs of functional impairment on neuropsychologic testing or of brain atrophy by neuroimaging (Minoshima et al., 1997).”
BackgroundABAD Directly Links Aß to Mitochondrial Toxicity in Alzheimer's Disease
Lustbader, J. W., Cirilli, M., Lin, C., Xu, H. W., Takuma, K., Wang, N., Caspersen, C., Chen, X., Pollak, S., Chaney, M., et al. (2004) · Science · doi:10.1126/science.1091230 · Cited by 1,303
Mitochondrial abnormalities in Alzheimer brain: Mechanistic implications
Bubber, P., Haroutunian, V., Fisch, G., Blass, J. P., & Gibson, G. E. (2005) · Annals of Neurology · doi:10.1002/ana.20474 · Cited by 622
Cytochrome c oxidase is decreased in Alzheimer’s disease platelets
Cardoso, S. M., Proença, M. T., Santos, S., Santana, I., & Oliveira, C. R. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(03)00033-2 · Cited by 281 · cited 3×
“In turn it seems that Ab neurotoxicity is enhanced by abnormal mitochondrial function in ‘‘cybrid’’ cells that harbor mitochondrial DNA from AD patients (Cardoso et al., 2004a).”
BackgroundInfluentialOxidatively damaged proteins of heart mitochondrial electron transport complexes
Choksi, K. B., Boylston, W. H., Rabek, J. P., Widger, W. R., & Papaconstantinou, J. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2003.11.007 · Cited by 212 · cited 1×
“This overproduction in turn could further damage mitochondrial enzymes, leading to a vicious cycle (Choksi et al., 2004).”
BackgroundFunctional mitochondria are required for amyloid β‐mediated neurotoxicity
Cardoso, S. M., Santos, S., Swerdlow, R. H., & Oliveira, C. R. (2001) · The FASEB Journal · doi:10.1096/fj.00-0561fje · Cited by 203 · cited 1×
“It has been reported that Ab induces cytochrome c release and caspase activation only in cells with a functional respiratory chain (Cardoso et al., 2001; Morais Cardoso et al., 2002).”
Backgroundβ‐Amyloid fragment 25–35 selectively decreases complex IV activity in isolated mitochondria
Canevari, L., Clark, J. B., & Bates, T. E. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01028-5 · Cited by 196
Cited by
Neuroprotective effects of huperzine A: New therapeutic targets for neurodegenerative disease
Zhang, H. Y., & Tang, X. C. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.10.004 · Cited by 174
Peng, Y., Gao, P., Shi, L., Chen, L., Liu, J., & Long, J. (2020) · Antioxidants & Redox Signaling · doi:10.1089/ars.2019.7763 · Cited by 110
Natural Phytochemicals in the Treatment and Prevention of Dementia: An Overview
Libro, R., Giacoppo, S., Soundara Rajan, T., Bramanti, P., & Mazzon, E. (2016) · Molecules · doi:10.3390/molecules21040518 · Cited by 107
Korábečný, J., Nepovimová, E., Cikánková, T., Špilovská, K., Vašková, L., Mezeiová, E., Kuča, K., & Hroudová, J. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2017.06.034 · Cited by 64
Metadata
- Authors
- Gao, X., & Tang, X. C.
- Venue
- Journal of Neuroscience Research
- Publisher
- Wiley
- Published
- 2006-02-21
- Volume
- 83
- Issue
- 6
- Pages
- 1048-1057
- ISSN
- 0360-4012 (ISSN-L)
- 1097-4547
- OpenAlex
- W2029395883
- Cited by
- 67
- References
- 12
- FWCI
- 2.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.